6β-hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects

Drug Metabolism and Disposition

Volumn 42, Issue 4, 2014, Pages 685-694

  Imamura, Yuichiro ^a   Tsuruya, Yuri ^d   Damme, Katja ^a   Heer, Dominik ^a   Kumagai, Yuji ^b   Maeda, Kazuya ^d   Murayama, Nobuyuki ^a   Okudaira, Noriko ^a   Kurihara, Atsushi ^a   Izumi, Takashi ^a   Sugiyama, Yuichi ^c   Kusuhara, Hiroyuki ^d  

^a DAIICHI SANKYO CO   (Japan)

^b KITASATO UNIVERSITY HOSPITAL   (Japan)

^c RIKEN   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; 6BETA HYDROXYHYDROCORTISONE; ADEFOVIR DIPIVOXIL; BICILLIN G; CYTOCHROME P450 3A4; HYDROCORTISONE; METFORMIN; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; ORGANIC ANION TRANSPORTER 3; PENICILLIN G; PROBENECID; PYRIMETHAMINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CONCENTRATION; DRUG EFFECT; DRUG TRANSPORT; DRUG UPTAKE; ENZYME ACTIVITY; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; HYDROXYLATION; KIDNEY CLEARANCE; KIDNEY CONCENTRATING CAPACITY; KIDNEY SLICE; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE EXCRETION; LIVER MICROSOME; MALE; MIDDLE AGED; MOUSE; NONHUMAN; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; URINALYSIS; URINARY EXCRETION; WILD TYPE; YOUNG ADULT;

ADULT; ANIMALS; BIOLOGICAL MARKERS; CELL CULTURE TECHNIQUES; DRUG INTERACTIONS; FEMALE; HEALTHY VOLUNTEERS; HEK293 CELLS; HUMANS; HYDROCORTISONE; KIDNEY; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, KNOCKOUT; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; ORGANIC CATION TRANSPORT PROTEINS; PHARMACEUTICAL PREPARATIONS; SUBSTRATE SPECIFICITY; YOUNG ADULT;

EID: 84896104721     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.055475     Document Type: Article

References (46)

1. Abel SM, Maggs JL, Back DJ, and Park BK (1992) Cortisol metabolism by human liver in vitro - I. Metabolite identification and inter-individual variability. J Steroid Biochem Mol Biol 43:713-719. (Pubitemid 23002504)
2. Asif AR, Steffgen J, Metten M, Grunewald RW, Müller GA, Bahn A, Burckhardt G, and Hagos Y (2005) Presence of organic anion transporters 3 (OAT3) and 4 (OAT4) in human adrenocortical cells. Pflugers Arch 450:88-95. (Pubitemid 40674733)
3. Brown RW, Chapman KE, Kotelevtsev Y, Yau JL, Lindsay RS, Brett L, Leckie C, Murad P, Lyons V, Mullins JJ, Edwards CR, and Seckl JR (1996) Cloning and production of antisera to human placental 11 beta-hydroxysteroid dehydrogenase type 2. Biochem J 313:1007-1017. (Pubitemid 26050840)
4. Burckhardt G (2012) Drug transport by Organic Anion Transporters (OATs). Pharmacol Ther 136:106-130.
5. Chan WK, Nguyen LT, Miller VP, and Harris RZ (1998) Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine. Life Sci 62:PL135-PL142. (Pubitemid 28077897)
6. Cihlar T and Ho ES (2000) Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1. Anal Biochem 283:49-55. (Pubitemid 30469749)
7. DeGorter MK, Xia CQ, Yang JJ, and Kim RB (2012) Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol 52:249-273.
8. Deguchi T, Kusuhara H, Takadate A, Endou H, Otagiri M, and Sugiyama Y (2004) Characterization of uremic toxin transport by organic anion transporters in the kidney. Kidney Int 65:162-174. (Pubitemid 38037501)
9. Diczfalusy U, Nylén H, Elander P, and Bertilsson L (2011) 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. Br J Clin Pharmacol 71:183-189.
10. Enomoto A, Takeda M, Taki K, Takayama F, Noshiro R, Niwa T, and Endou H (2003) Interactions of human organic anion as well as cation transporters with indoxyl sulfate. Eur J Pharmacol 466:13-20. (Pubitemid 36385086)
11. Fromm MF (2012) Prediction of transporter-mediated drug-drug interactions using endogenous compounds. Clin Pharmacol Ther 92:546-548.
12. Furuta T, Suzuki A, Mori C, Shibasaki H, Yokokawa A, and Kasuya Y (2003) Evidence for the validity of cortisol 6 beta-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans. Drug Metab Dispos 31:1283-1287. (Pubitemid 37310312)
13. Galteau MM and Shamsa F (2003) Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol 59:713-733. (Pubitemid 38041296)
14. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, and Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
15. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE, and Koepsell H (1997) Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 16:871-881. (Pubitemid 27332696)
16. Imamura Y, Murayama N, Okudaira N, Kurihara A, Inoue K, Yuasa H, Izumi T, Kusuhara H, and Sugiyama Y (2013) Effect of the fluoroquinolone antibacterial agent DX-619 on the apparent formation and renal clearances of 6β-hydroxycortisol, an endogenous probe for CYP3A4 inhibition, in healthy subjects. Pharm Res 30:447-457.
17. Imamura Y, Murayama N, Okudaira N, Kurihara A, Okazaki O, Izumi T, Inoue K, Yuasa H, Kusuhara H, and Sugiyama Y (2011) Prediction of fluoroquinolone- induced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion. Clin Pharmacol Ther 89:81-88.
18. Ito S, Kusuhara H, Kumagai Y, Moriyama Y, Inoue K, Kondo T, Nakayama H, Horita S, Tanabe K, and Yuasa H, et al. (2012) N-methylnicotinamide is an endogenous probe for evaluation of drug-drug interactions involving multidrug and toxin extrusions (MATE1 and MATE2-K). Clin Pharmacol Ther 92:635-641.
19. Ito S, Kusuhara H, Kuroiwa Y, Wu C, Moriyama Y, Inoue K, Kondo T, Yuasa H, Nakayama H, and Horita S, et al. (2010) Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine. J Pharmacol Exp Ther 333:341-350.
20. Kato K, Mori H, Kito T, Yokochi M, Ito S, Inoue K, Yonezawa A, Katsura T, Kumagai Y, and Yuasa H, et al. (2014) Investigation of endogenous compounds for assessing the drug interactions in the urinary excretion involving multidrug and toxin extrusion proteins. Pharm Res 31:136-147.
21. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, and Endou H (2004) Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci 94:197-202. (Pubitemid 38405135)
22. König J, Müller F, and Fromm MF (2013) Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol Rev 65:944-966.
23. Kusuhara H, Ito S, Kumagai Y, Jiang M, Shiroshita T, Moriyama Y, Inoue K, Yuasa H, and Sugiyama Y (2011) Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther 89:837-844.
24. Kusuhara H and Sugiyama Y (2009) In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab Pharmacokinet 24:37-52.
25. Kusuhara H, Yoshida K, and Sugiyama Y (2013) In vivo characterization of on interactions on transporters, in Transporters in Drug Development (Sugiyama Y and Steffansen B eds) pp 67-98, Springer, New York.
26. Masereeuw R and Russel FG (2010) Therapeutic implications of renal anionic drug transporters. Pharmacol Ther 126:200-216.
27. Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T, Ogawa O, and Inui K (2006) Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 17:2127-2135. (Pubitemid 44141902)
28. Matsushima S, Maeda K, Inoue K, Ohta KY, Yuasa H, Kondo T, Nakayama H, Horita S, Kusuhara H, and Sugiyama Y (2009) The inhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine. Drug Metab Dispos 37:555-559.
29. Nigam SK, Bush KT, and Bhatnagar V (2007) Drug and toxicant handling by the OAT organic anion transporters in the kidney and other tissues. Nat Clin Pract Nephrol 3:443-448. (Pubitemid 47123587)
30. Nozaki Y, Kusuhara H, Kondo T, Hasegawa M, Shiroyanagi Y, Nakazawa H, Okano T, and Sugiyama Y (2007a) Characterization of the uptake of organic anion transporter (OAT) 1 and OAT3 substrates by human kidney slices. J Pharmacol Exp Ther 321:362-369. (Pubitemid 46456974)
31. Nozaki Y, Kusuhara H, Kondo T, Iwaki M, Shiroyanagi Y, Nakayama H, Horita S, Nakazawa H, Okano T, and Sugiyama Y (2007b) Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. J Pharmacol Exp Ther 322:1162-1170.
32. Ohta KY, Imamura Y, Okudaira N, Atsumi R, Inoue K, and Yuasa H (2009) Functional characterization of multidrug and toxin extrusion protein 1 as a facilitative transporter for fluoroquinolones. J Pharmacol Exp Ther 328:628-634.
33. Peng CC, Templeton I, Thummel KE, Davis C, Kunze KL, and Isoherranen N (2011) Evaluation of 6β-hydroxycortisol, 6β-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 89:888-895.
34. Selen A, Amidon GL, and Welling PG (1982) Pharmacokinetics of probenecid following oral doses to human volunteers. J Pharm Sci 71:1238-1242. (Pubitemid 13230064)
35. Sweet DH, Miller DS, Pritchard JB, Fujiwara Y, Beier DR, and Nigam SK (2002) Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J Biol Chem 277:26934-26943. (Pubitemid 34951703)
36. Tahara H, Kusuhara H, Endou H, Koepsell H, Imaoka T, Fuse E, and Sugiyama Y (2005) A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther 315:337-345. (Pubitemid 41380529)
37. Tahara H, Kusuhara H, Maeda K, Koepsell H, Fuse E, and Sugiyama Y (2006) Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid. Drug Metab Dispos 34:743-747.
38. Takahara N, Saga T, Inubushi M, Kusuhara H, Seki C, Ito S, Oyama N, Yokoyama O, Sugiyama Y, and Fujibayashi Y (2013) Drugs interacting with organic anion transporter-1 affect uptake of Tc-99m-mercaptoacetyl-triglycine (MAG3) in the human kidney: therapeutic drug interaction in Tc-99m-MAG3 diagnosis of renal function and possible application of Tc-99m-MAG3 for drug development. Nucl Med Biol 40:643-650.
39. Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, and Inui K (2007) Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol 74:359-371. (Pubitemid 46890818)
40. Urakami Y, Kimura N, Okuda M, and Inui K (2004) Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm Res 21:976-981. (Pubitemid 38870147)
41. Vallon V, Eraly SA, Wikoff WR, Rieg T, Kaler G, Truong DM, Ahn SY, Mahapatra NR, Mahata SK, and Gangoiti JA, et al. (2008) Organic anion transporter 3 contributes to the regulation of blood pressure. J Am Soc Nephrol 19:1732-1740.
42. Vanwert AL, Bailey RM, and Sweet DH (2007) Organic anion transporter 3 (Oat3/Slc22a8) knockout mice exhibit altered clearance and distribution of penicillin G. Am J Physiol Renal Physiol 293:F1332-F1341. (Pubitemid 47583969)
43. Wang L and Sweet DH (2013) Renal organic anion transporters (SLC22 family): expression, regulation, roles in toxicity, and impact on injury and disease. AAPS J 15:53-69.
44. Wikoff WR, Nagle MA, Kouznetsova VL, Tsigelny IF, and Nigam SK (2011) Untargeted metabolomics identifies enterobiome metabolites and putative uremic toxins as substrates of organic anion transporter 1 (Oat1). J Proteome Res 10:2842-2851.
45. Yamaoka K, Tanigawara Y, Nakagawa T, and Uno T (1981) A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 4:879-885. (Pubitemid 12174128)
46. Yoshida K, Maeda K, and Sugiyama Y (2013) Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms. Annu Rev Pharmacol Toxicol 53:581-612.